Prediction of Risk Factors for Adverse Events After Head and Neck Vascular Recanalization Surgery Based on Machine Learning Models

Tang-Du Hospital

Status: Completed

Conditions: Machine Learning

Treatments: Other: observe

Study type: Observational

Funder types: Other

Identifiers

NCT06120478

Bei Liu

Details and patient eligibility

About

Prediction of risk factors for adverse events after head and neck vascular recanalization surgery based on machine learning models

Enrollment: 1,300 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All enrolled patients were diagnosed with clear head and neck artery stenosis and a risk event after head and neck revascularization;
• Location of lesion: origin of internal carotid artery, bifurcation of internal and external carotid arteries;
• Patients with symptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, and with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 50% found on angiography;
• Asymptomatic head and neck artery stenosis and risk events after head and neck revascularization, with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 60% found on angiography;
• Asymptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, with a non-invasive examination of stenosis degree less than 70%, but angiography or other examinations indicate that the stenosis lesion is in an unstable state;
• Symptomatic head and neck artery stenosis and risk events after head and neck revascularization, non-invasive examination of head and neck artery stenosis and risk events after head and neck revascularization are 50% to 69%;
• Sign the project informed consent form

Exclusion criteria

• Patients with poor overall condition and intolerance to general anesthesia;
• Patients with mental illness or severe mental illness;
• Severe respiratory system diseases;
• Pregnant and lactating women;
• Participating in another clinical study;
• Patients with advanced tumors or those who are expected to die within one year;

Trial design

1,300 participants in 2 patient groups

xi'an

Treatment:

Other: observe

shanxi

Treatment:

Other: observe